X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ABBOTT INDIA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ABBOTT INDIA GLENMARK PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 23.1 35.7 64.8% View Chart
P/BV x 3.2 9.2 34.3% View Chart
Dividend Yield % 0.3 0.8 44.3%  

Financials

 GLENMARK PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
ABBOTT INDIA
Mar-18
GLENMARK PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs9306,110 15.2%   
Low Rs5173,996 12.9%   
Sales per share (Unadj.) Rs322.61,552.2 20.8%  
Earnings per share (Unadj.) Rs28.5188.8 15.1%  
Cash flow per share (Unadj.) Rs39.2196.4 20.0%  
Dividends per share (Unadj.) Rs2.0055.00 3.6%  
Dividend yield (eoy) %0.31.1 25.4%  
Book value per share (Unadj.) Rs183.0796.6 23.0%  
Shares outstanding (eoy) m282.1721.25 1,327.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.3 68.9%   
Avg P/E ratio x25.426.8 94.9%  
P/CF ratio (eoy) x18.525.7 71.8%  
Price / Book Value ratio x4.06.3 62.3%  
Dividend payout %7.029.1 24.1%   
Avg Mkt Cap Rs m204,206107,376 190.2%   
No. of employees `00013.73.3 412.9%   
Total wages/salary Rs m18,7183,937 475.5%   
Avg. sales/employee Rs Th6,636.89,929.3 66.8%   
Avg. wages/employee Rs Th1,364.71,185.1 115.2%   
Avg. net profit/employee Rs Th586.11,207.7 48.5%   
INCOME DATA
Net Sales Rs m91,03132,985 276.0%  
Other income Rs m9141,170 78.1%   
Total revenues Rs m91,94534,155 269.2%   
Gross profit Rs m16,1545,245 308.0%  
Depreciation Rs m3,019162 1,864.6%   
Interest Rs m2,85638 7,475.7%   
Profit before tax Rs m11,1936,215 180.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1552,203 143.2%   
Profit after tax Rs m8,0394,012 200.4%  
Gross profit margin %17.715.9 111.6%  
Effective tax rate %28.235.4 79.5%   
Net profit margin %8.812.2 72.6%  
BALANCE SHEET DATA
Current assets Rs m69,88722,655 308.5%   
Current liabilities Rs m32,8796,681 492.1%   
Net working cap to sales %40.748.4 83.9%  
Current ratio x2.13.4 62.7%  
Inventory Days Days8165 125.7%  
Debtors Days Days9329 320.7%  
Net fixed assets Rs m28,892835 3,458.1%   
Share capital Rs m282213 132.8%   
"Free" reserves Rs m51,35316,715 307.2%   
Net worth Rs m51,63516,928 305.0%   
Long term debt Rs m41,4180-   
Total assets Rs m125,95424,162 521.3%  
Interest coverage x4.9163.7 3.0%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.71.4 52.9%   
Return on assets %8.616.8 51.6%  
Return on equity %15.623.7 65.7%  
Return on capital %15.136.9 40.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,317369 9,854.3%   
Fx outflow Rs m9,7203,807 255.3%   
Net fx Rs m26,598-3,438 -773.6%   
CASH FLOW
From Operations Rs m16,4811,527 1,079.3%  
From Investments Rs m-10,133-2,148 471.7%  
From Financial Activity Rs m-4,685-1,024 457.4%  
Net Cashflow Rs m1,770-1,646 -107.6%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 7.9 87.3%  
FIIs % 34.4 0.1 34,400.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   56,727 18,270 310.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS